Understanding sorafenib-induced ferroptosis and resistance mechanisms: Implications for cancer therapy

Area of Science:

• Oncology
• Nanomedicine
• Cell Death Mechanisms

Background:

• Sorafenib is a first-line liver cancer treatment with a known safety profile.
• Novel therapies may offer better efficacy but present safety and cost challenges.
• Sorafenib induces apoptosis and ferroptosis, a recognized form of immunogenic cell death.

Purpose of the Study:

• To review mechanisms of Sorafenib-induced ferroptosis and resistance.
• To outline nanomedicine strategies for overcoming ferroptosis resistance.
• To summarize biomarkers for predicting Sorafenib resistance.

Main Methods:

• Literature review of Sorafenib mechanisms, resistance pathways, and nanomedicine applications.
• Analysis of studies on ferroptosis induction and immunogenic cell death.
• Compilation of data on molecular biomarkers associated with Sorafenib resistance.

Main Results:

• Sorafenib's dual action includes apoptosis and ferroptosis induction.
• Resistance to Sorafenib-induced ferroptosis is a significant clinical challenge.
• Nanomedicines show promise in enhancing Sorafenib efficacy by overcoming resistance.

Conclusions:

• Understanding Sorafenib-induced ferroptosis and resistance is crucial for optimizing liver cancer therapy.
• Nanomedicine offers innovative approaches to potentiate Sorafenib's anti-cancer effects.
• Biomarker identification can guide personalized treatment strategies for Sorafenib therapy.